Quantcast
Last updated on April 24, 2014 at 13:15 EDT

Latest Vitrectomy Stories

2013-11-20 16:26:25

LEUVEN, Belgium, November 20, 2013 /PRNewswire/ -- Canada is the first market launch for JETREA(R) outside the US and Europe ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. Canada is the first market where...

2013-10-22 20:21:33

LEUVEN, Belgium, October 23, 2013 /PRNewswire/ -- Final guidance confirms metamorphopsia, an early symptom of VMT, as severe and distressing, requiring early treatment - NICE final guidance recommends reimbursement of JETREA for treatment of a broad range of VMT patients, from early stage to late-stage: patients with epiretinal membranes (ERMs) are excluded - NICE recommends reimbursement for...

2013-10-21 04:20:59

LEUVEN, Belgium, October 21, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA(R) (ocriplasmin) is nominated for the 2013 Prix Galien USA Award in the Best Biotechnology Product category. The Prix Galien USA, now in its seventh year, is an international award that recognizes outstanding achievements in improving human health...

2013-09-02 12:20:43

LEUVEN, Belgium, September 2, 2013 /PRNewswire/ -- Metamorphopsia confirmed as a severe and distressing symptom deserving immediate attention and early treatment with reimbursement - NICE FAD recommending reimbursement of JETREA for treatment of VMT patients, from early stage to late-stage (full thickness macular hole (FTMH) < 400 microns), when severe and distressing symptoms; patients with ERMs are...

2013-08-16 12:24:24

LEUVEN, Belgium, August 16, 2013 /PRNewswire/ -- Canada is first market outside the US and Europe where JETREA(R) is approved ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has approved JETREA(R) (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). The priority review of the New Drug Submission for...

2013-08-16 12:24:21

-- JETREA(TM) injection represents a breakthrough for patients with symptomatic vitreomacular adhesion, a progressive eye condition often responsible for retinal distortion, vision deterioration, and irreversible damage and loss of vision1,2,3,4,5,6 -- One-time intravitreal injection of JETREA(TM) has shown efficacy in resolution of vitreomacular adhesion, compared to placebo at day 281,2...

2013-08-02 04:20:37

LEUVEN, Belgium, August 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA(R) (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when...

2013-06-12 00:20:39

LEUVEN, Belgium, June 12, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA(R) (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA(R) as an option...

2013-05-27 12:20:49

LEUVEN, Belgium, May 27, 2013 /PRNewswire/ -- Roll out in Finland and Norway to follow shortly ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) in Denmark and Sweden, the third and fourth European markets where the product is now available. Alcon will roll out the drug in Finland and...

2013-05-02 04:21:38

LEUVEN, Belgium, May 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R)in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA(R)is listed in the "Lauer-Taxe" (Grosse Deutsche Spezialitatentaxe) with an ex-factory price of EUR3,078....